Only now the Natural Birth package is 2 000 PLN cheaper at Medicover Hospital!

Professional care during childbirth and comfortable stay conditions.

1500 visits available 1500 visits available
 3788 doctors 3788 doctors
1800 blood tests and services 1800 blood tests and services
Verified opinions Verified opinions
Mediclub

Anti-HCV antibodies met. RIBA

Recombinant ImmunoBlot Assay (RIBA) is a blood test that detects antibodies to hepatitis C virus (HCV), used as a secondary confirmatory test if the initial screening test for HCV is positive or indeterminate.

City
City
Supplier
Supplier
Sort by
Sort by

Synevo

from PLN 307.00 Mediclub logo Mediclub logo from PLN 291.00
+ Material collection fee
Lowest price from 30 days before discounting PLN 291.00
  • Test description
  • Documents
Test description

Bodies p/HCV met. RIBA

Clinical significance

HCV -HCV virus belongs to the Flaviviridae family, and causes hepatitis C. The virus is transmitted through contact with blood and infected tissues, including as maternal-fetal infections and through sexual contact. The incubation period of the disease averages 50 days (15-160 days). The HCV virus replicates predominantly in the liver, less frequently in B lymphocytes or mób tissue. The disease can have an acute or chronic course, as a consequence of which cirrhosis or primary liver cancer can develop. Early detection of infection allows to start therapy, eliminate or slow down the disease. Hepatitis C diagnosis includes, at the first stage, the determination of anti-HCV antibodies, whichóre detected in the blood 4-10 weeks after infection. In immunodeficient and dialysis patients, the test result may be falsely negative. A qualitative HCV RNA assay is performed to confirm infection. Viral replication testing with quantitative HCV RNA determination allows determination of infection activity. There are 6 main genotypesów, rów differing in sensitivity to antiviral drugs. For this reason, HCV genotyping is performed in HCV diagnosis to assess prognosis, type and duration of therapy. During treatment, the amount of viral genetic material in the blood is evaluated to assess the effectiveness of treatment.

Patient preparation

Material: Serum

Documents